(R)-Chloroquine

(R)-Chloroquine

SCHEMBL134500

CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 1.00
CHRM4 P08173 3/20 1.00
CHRM5 P08912 3/20 1.00
ADRA2A P08913 3/20 1.00
CHRM1 P11229 3/20 1.00
ADRA2B P18089 3/20 1.00
ADRA2C P18825 3/20 1.00
CHRM3 P20309 3/20 1.00
KCNH2 Q12809 3/20 1.00
TMEM97 Q5BJF2 2/20 1.00
SIGMAR1 Q99720 2/20 1.00
ACE2 Q9BYF1 2/20 1.00
NR4A2 P43354 2/20 1.00
CYP2D6 P10635 2/20 1.00
PRNP P04156 2/20 1.00
MTOR P42345 2/20 1.00
CYP2C19 P33261 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
APP P05067 1/20 1.00
NQO2 P16083 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chloroquine SCHEMBL8933 1.00 CHRM2 (1.00) CHRM2CHRM4CHRM5ADRA2ACHRM1
(R)-Chloroquine SCHEMBL29429108 1.00 CHRM2 (1.00) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL29363614 1.00 CHRM2 (1.00) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL8474661 1.00 CHRM2 (1.00) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL8934 1.00 CHRM2 (1.00) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL23854336 0.99 CHRM2 (0.98) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL3302947 0.99 CHRM2 (0.98) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL5488804 0.99 CHRM2 (0.98) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL9862220 0.99 CHRM2 (0.98) CHRM2CHRM4CHRM5ADRA2ACHRM1
Chloroquine SCHEMBL22534361 0.99 CHRM2 (0.98) CHRM2CHRM4CHRM5ADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347012-B1 PHOTOTHERAPY TREATMENT DEVICE LUCIBEL SA (FR) 2026-05-06 EP claimed
EP-4633638-A1 TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) Luminous Mind Inc. (US) 2025-10-22 EP claimed
CN-107846890-B Herbicidal composition comprising cycloheptane and a specific phytoene desaturase inhibitor 巴斯夫农业公司 2024-09-03 CN claimed
WO-2024138897-A1 NANOBODY TARGETING BCMA, CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF 河北森朗生物科技有限公司 2024-07-04 WO claimed
WO-2024130044-A1 TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) LUMINOUS MIND INC. (US) 2024-06-20 WO claimed
EP-3324931-B1 IN SITU CROSS-LINKABLE POLYSACCHARIDE COMPOSITIONS AND USES THEREOF MERZ PHARMA GMBH & CO KGAA (DE) 2023-11-29 EP claimed
CN-113354581-B Preparation method and application of chiral chloroquine and phosphate thereof 华南理工大学 2023-06-20 CN claimed
WO-2023069981-A1 USES OF TAXIFOLIN FOR RESPIRATORY HEALTH PHYTO TECH CORP. (US) 2023-04-27 WO claimed
US-20230119141-A1 USES OF TAXIFOLIN FOR RESPIRATORY HEALTH PHYTO TECH CORP. 2023-04-20 US claimed
WO-2021231314-A1 METHODS OF TREATING COVID-19 USING TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS INC. (US) 2021-11-18 WO claimed
EP-1448220-A2 ANTIPHLOGISTIC AGENT AND THE USE THEREOF Kosmas KG (DE) 2004-08-25 EP claimed
WO-2003045416-A2 ANTIPHLOGISTIC AGENT AND THE USE THEREOF KOSMAS KG (DE) 2003-06-05 WO claimed
WO-2003039552-A1 COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG ALTANA PHARMA AG (DE) 2003-05-15 WO claimed
CN-1062133-C Medicine for treating hypertensional sickness CHANG PEIRUN (CN) 2001-02-21 CN claimed
CN-1060339-C Antirheumatic capsule capable of controlling inflammation and skeleton deformation of rheumatoid disease SHEN CHUNLOU (CN) 2001-01-10 CN claimed
CN-1200269-A Medicine for treating hypertensional sickness CHANG PEIRUN (CN) 1998-12-02 CN claimed
EP-0879605-A2 GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE HOECHST AKTIENGESELLSCHAFT (DE) 1998-11-25 EP claimed
CN-1174035-A Antirheumatic capsule capable of controlling inflammation and skeleton deformation of rheumatoid disease SHEN CHUNLOU (CN) 1998-02-25 CN claimed
US-4753984-A Water soluble macromolecular prodrugs, their preparation and their use as antitumor and antiparasite medicines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1988-06-28 US claimed
EP-0137868-A1 1-Substituted imidazole-5-carboxylic-acid derivatives, their preparation and their use as biocides HOECHST AKTIENGESELLSCHAFT (DE) 1985-04-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119141-A1 USES OF TAXIFOLIN FOR RESPIRATORY HEALTH ACE2, MAVS, ACE CHRM2 4376/4885CHRM4 4237/4885CHRM5 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.